1. Home
  2. PSTV vs SYNX Comparison

PSTV vs SYNX Comparison

Compare PSTV & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • SYNX
  • Stock Information
  • Founded
  • PSTV 1996
  • SYNX 2005
  • Country
  • PSTV United States
  • SYNX Israel
  • Employees
  • PSTV N/A
  • SYNX N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • SYNX
  • Sector
  • PSTV Health Care
  • SYNX
  • Exchange
  • PSTV Nasdaq
  • SYNX Nasdaq
  • Market Cap
  • PSTV 12.2M
  • SYNX 11.9M
  • IPO Year
  • PSTV N/A
  • SYNX 2024
  • Fundamental
  • Price
  • PSTV $0.42
  • SYNX $1.93
  • Analyst Decision
  • PSTV Strong Buy
  • SYNX
  • Analyst Count
  • PSTV 3
  • SYNX 0
  • Target Price
  • PSTV $12.75
  • SYNX N/A
  • AVG Volume (30 Days)
  • PSTV 3.3M
  • SYNX 31.4K
  • Earning Date
  • PSTV 05-23-2025
  • SYNX 05-14-2025
  • Dividend Yield
  • PSTV N/A
  • SYNX N/A
  • EPS Growth
  • PSTV N/A
  • SYNX N/A
  • EPS
  • PSTV N/A
  • SYNX N/A
  • Revenue
  • PSTV $5,824,000.00
  • SYNX $9,094,000.00
  • Revenue This Year
  • PSTV $13.26
  • SYNX N/A
  • Revenue Next Year
  • PSTV $8.84
  • SYNX N/A
  • P/E Ratio
  • PSTV N/A
  • SYNX N/A
  • Revenue Growth
  • PSTV 18.54
  • SYNX 19.14
  • 52 Week Low
  • PSTV $0.24
  • SYNX $1.70
  • 52 Week High
  • PSTV $2.67
  • SYNX $6.49
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 36.71
  • SYNX 44.02
  • Support Level
  • PSTV $0.49
  • SYNX $1.78
  • Resistance Level
  • PSTV $0.75
  • SYNX $2.06
  • Average True Range (ATR)
  • PSTV 0.10
  • SYNX 0.13
  • MACD
  • PSTV -0.01
  • SYNX 0.07
  • Stochastic Oscillator
  • PSTV 4.23
  • SYNX 63.89

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: